Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1980 Dec;42(6):831–840. doi: 10.1038/bjc.1980.330

Prognostic features in the third MRC myelomatosis trial. Medical Research Council's Working Party on Leukaemia in Adults.

PMCID: PMC2010574  PMID: 7459218

Abstract

This paper reports the prognostic significance of clinical and laboratory features recorded at presentation in 485 patients entered into the Medical Research Council's 3rd therapeutic trial in myelomatosis between July 1975 and August 1978. The data were complete up to 1 January 1980, with a median follow-up time of 36 months. The 3 major determinants of prognosis were the blood urea concentration (BUC), the haemoglobin concentration ([Hb]), and the clinical performance status. Three prognostic groups based on these determinants were specified. The groups contained 22%, 56% and 22% of the patients and gave 2-year survival probabilities of 76%, 50% and 9% respectively. Patients in the good-prognosis group had a BUC less than or equal to 8 mM. [Hb] greater than or equal to 100 g/l, and no or minimal symptoms. Those in the poor-prognosis group had either [Hb] less than or equal to 75 g/l or a BUC greater than 10 mM and restricted clinical activity. Patients who had combinations of the 3 determinant features which excluded them from these 2 groups were classified into an intermediate prognosis group.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alexanian R., Balcerzak S., Bonnet J. D., Gehan E. A., Haut A., Hewlett J. S., Monto R. W. Prognostic factors in multiple myeloma. Cancer. 1975 Oct;36(4):1192–1201. doi: 10.1002/1097-0142(197510)36:4<1192::aid-cncr2820360403>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  2. Durie B. G., Salmon S. E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975 Sep;36(3):842–854. doi: 10.1002/1097-0142(197509)36:3<842::aid-cncr2820360303>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  3. Leonard R. C., MacLennan I. C., Smart Y., Vanhegan R. I., Cuzick J. Light chain isotype-associated suppression of normal plasma cell numbers in patients with multiple myeloma: Medical Research Council's Working Party for Leukaemia in Adults and the Oxford Lymphoma Group. Int J Cancer. 1979 Oct 15;24(4):385–393. doi: 10.1002/ijc.2910240402. [DOI] [PubMed] [Google Scholar]
  4. Matzner Y., Benbassat J., Polliack A. Prognostic factors in multiple myeloma: a retrospective study using conventional statistical methods and a computer program. Acta Haematol. 1978;60(5):257–268. doi: 10.1159/000207722. [DOI] [PubMed] [Google Scholar]
  5. Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto J., Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer. 1976 Dec;34(6):585–612. doi: 10.1038/bjc.1976.220. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Salmon S. E., Smith B. A. Immunoglobulin synthesis and total body tumor cell number in IgG multiple myeloma. J Clin Invest. 1970 Jun;49(6):1114–1121. doi: 10.1172/JCI106327. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Woodruff R. K., Wadsworth J., Malpas J. S., Tobias J. S. Clinical staging in multiple myeloma. Br J Haematol. 1979 Jun;42(2):199–205. doi: 10.1111/j.1365-2141.1979.tb01124.x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES